OR WAIT null SECS
June 24, 2025
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
June 23, 2025
A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.
Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling.
June 20, 2025
The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.
June 19, 2025
NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.
Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.
The new facility offers cleanroom packaging and high-sensitivity analytical testing.
June 18, 2025
The Commissioner’s National Priority Voucher can be used by drug developers to participate in a novel priority program for shortened drug approval review time.
The contest, which aims to accelerate the development of recombinant protein-based oncology therapies, will culminate at CPHI Frankfurt in October 2025.
June 17, 2025
Chrysalis lists among its partners early-stage biotechnology companies, contract research organizations, top-10 pharmaceutical firms, and various other life sciences stakeholders.